HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)

Conditions: Hepatocellular Carcinoma With PVTT Interventions: Drug: Tislelizumab; Drug: Lenvatinib Sponsors: Li Xiao Wei Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials